HomeCompareBSX vs CEQP

BSX vs CEQP: Dividend Comparison 2026

BSX yields 3.18% · CEQP yields 9.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CEQP wins by $153.6K in total portfolio value
10 years
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →
CEQP
CEQP
● Live price
9.27%
Share price
$28.26
Annual div
$2.62
5Y div CAGR
25.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$173.8K
Annual income
$54,802.53
Full CEQP calculator →

Portfolio growth — BSX vs CEQP

📍 CEQP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBSXCEQP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BSX + CEQP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BSX pays
CEQP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
CEQP
Annual income on $10K today (after 15% tax)
$788.04/yr
After 10yr DRIP, annual income (after tax)
$46,582.15/yr
At 15% tax rate, CEQP beats the other by $46,581.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BSX + CEQP for your $10,000?

BSX: 50%CEQP: 50%
100% CEQP50/50100% BSX
Portfolio after 10yr
$97.0K
Annual income
$27,401.42/yr
Blended yield
28.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
CEQP
Analyst Ratings
8
Buy
9
Hold
1
Sell
Consensus: Hold
Price Target
$33.00
+16.8% upside vs current
Range: $28.00 — $35.00
Altman Z
1.3
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BSX buys
6
CEQP buys
12
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
Kevin Hern🏢 House$BSX▼ Sell$15,001 - $50,0002025-10-28
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-10-17
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBSXCEQP
Forward yield3.18%9.27%
Annual dividend / share$2.00$2.62
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%25.6%
Portfolio after 10y$20.2K$173.8K
Annual income after 10y$0.32$54,802.53
Total dividends collected$321.00$137.2K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold
Analyst price target$108.35$33.00

Year-by-year: BSX vs CEQP ($10,000, DRIP)

YearBSX PortfolioBSX Income/yrCEQP PortfolioCEQP Income/yrGap
1← crossover$10,859$158.91$11,864$1,164.44$1.0KCEQP
2$11,700$80.63$14,317$1,621.71$2.6KCEQP
3$12,559$40.60$17,616$2,297.06$5.1KCEQP
4$13,459$20.36$22,167$3,317.73$8.7KCEQP
5$14,411$10.20$28,619$4,900.54$14.2KCEQP
6$15,425$5.10$38,049$7,426.80$22.6KCEQP
7$16,507$2.55$52,303$11,590.39$35.8KCEQP
8$17,664$1.28$74,666$18,701.89$57.0KCEQP
9$18,901$0.64$111,232$31,339.23$92.3KCEQP
10$20,225$0.32$173,821$54,802.53$153.6KCEQP

BSX vs CEQP: Complete Analysis 2026

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →

CEQPStock

Crestwood Equity Partners LP develops, acquires, owns, controls, and operates assets and operations in the energy midstream sector in the United States. It operates through three segments: Gathering and Processing North; Gathering and Processing South; and Storage and Logistics. The Gathering and Processing North segment offers natural gas, crude oil, and produced water gathering, compression, treating, processing, and disposal services to producers in the Williston Basin and Powder River Basin. This segment owns and operates natural gas facilities with approximately 0.4 Bcf/d of gathering capacity and 0.5 Bcf/d of processing capacity; crude oil facilities with approximately 150,000 Bbls/d of gathering capacity and 266,000 Bbls of storage capacity; and produced water facilities with approximately 130,000 Bbls/d of gathering and disposal capacity. The Gathering and Processing South segment provides natural gas gathering, compression, treating, and processing; and produced water gathering and disposal services to producers in the Marcellus, Barnett, and Delaware basins. This segment owns and operates natural gas facilities with 2.5 Bcf/d of gathering capacity and 0.7 Bcf/d of processing capacity; and produced water facilities with approximately 75,000 Bbls/d of gathering and disposal capacity. The Storage and Logistics segment offers natural gas liquids, crude oil, and natural gas storage, terminal, marketing, and transportation, including rail, truck and pipeline services to producers, refiners, marketers, utilities, and other customers. Crestwood Equity GP LLC serves as the general partner of Crestwood Equity Partners LP. The company was formerly known as Inergy L.P. and changed its name to Crestwood Equity Partners LP in October 2013. Crestwood Equity Partners LP was incorporated in 2001 and is headquartered in Houston, Texas.

Full CEQP Calculator →
📬

Get this BSX vs CEQP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BSX vs SCHDBSX vs JEPIBSX vs OBSX vs KOBSX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.